Sorted By Test Name - Mayo Medical Laboratories

DESIP
81854
DSG13
83680
1 0.35-0.69 Equivocal
2 0.70-3.49 Positive
3 3.50-17.4 Positive
4 17.5-49.9 Strongly positive
5 50.0-99.9 Strongly positive
6 > or =100 Strongly positive Reference values
apply to all ages.
Clinical References: Homburger HA: Allergic diseases. In Clinical Diagnosis and Management by
Laboratory Methods. 21st edition. Edited by McPherson RA, Pincus MR. WB Saunders, Publ, New York,
Chapter 53, Part VI, pp. 961-971, 2007
Desipramine, Serum
Clinical Information: Desipramine is a tricyclic antidepressant; it also is a metabolite of imipramine.
These drugs have also been employed in the treatment of enuresis (involuntary urination) in childhood
and severe obsessive-compulsive neurosis. Desipramine is the antidepressant of choice in patients where
maximal stimulation is indicated. The therapeutic concentration of desipramine is 100 to 300 ng/mL.
About 1 to 3 weeks of treatment are required before therapeutic effectiveness becomes apparent. The most
frequent side effects are those attributable to anticholinergic effects: dry mouth, constipation, dizziness,
tachycardia, palpitations, blurred vision, and urinary retention. These occur at blood concentrations in
excess of 300 ng/mL, although they may occur at therapeutic concentrations in the early stage of therapy.
Cardiac toxicity (first-degree heart block) is usually associated with blood concentrations in excess of 300
ng/mL.
Useful For: Monitoring serum concentration during therapy Evaluating potential toxicity The test may
also be useful to evaluate patient compliance
Interpretation: Most individuals display optimal response to desipramine with serum levels of 100 to
300 ng/mL. Some individuals may respond well outside of this range, or may display toxicity within the
therapeutic range; thus, interpretation should include clinical evaluation. Risk of toxicity is increased with
levels > or =300 ng/mL.
Reference Values:
Therapeutic concentration: 100-300 ng/mL
Toxic concentration: > or =300 ng/mL
Note: Therapeutic ranges are for specimens drawn at trough (ie, immediately before next scheduled
dose). Levels may be elevated in non-trough specimens.
Clinical References: 1. Wille SM, Cooreman SG, Neels HM, Lambert WE: Relevant issues in the
monitoring and toxicology of antidepressants. Crit Rev Clin Lab Sci 2008;45(1):25-89 2. Thanacoody
HK, Thomas SH: Antidepressant poisoning. Clin Med 2003 Mar-Apr;3(2):114-118 3. Baumann P,
Hiemke C, Ulrich S, et al: The AGNP-TDM expert group consensus guidelines: therapeutic drug
monitoring in psychiatry. Pharmacopsychiatry 2004;37:243-265
Desmoglein 1 (DSG1) and Desmoglein 3 (DSG3), Serum
Clinical Information: Pemphigus includes a group of often fatal autoimmune, blistering diseases
characterized by intraepithelial lesions. Pemphigus vulgaris and its variants may present with oral or
mucosal lesions alone or with mucosal plus skin lesions. Pemphigus foliaceous and variants present with
skin lesions alone. Indirect immunofluorescence (IIF) studies reveal that both forms of pemphigus are
caused by autoantibodies to cell surface antigens of stratified epithelia or mucous membranes and skin.
These antibodies bind to calcium-dependent adhesion molecules in cell surface desmosomes, notably
Current as of January 4, 2013 7:15 pm CST 800-533-1710 or 507-266-5700 or MayoMedicalLaboratories.com Page 608